Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5797498 | The Veterinary Journal | 2015 | 4 Pages |
â¢Rapidly proliferating cells have higher levels of activity of thymidine kinase (TK).â¢TK activity in serum is a potential biomarker for the presence of neoplasia.â¢Serum TK activity in horses with lymphoma was significantly higher than in healthy horses or horses with other tumours.â¢Serum TK activity is a potentially useful biomarker for equine lymphoma.
Serum thymidine kinase (sTK) activity is a tumour marker used as a prognostic indicator for lymphoma in humans, dogs and cats. The aim of this study was to evaluate the clinical utility of sTK as a biomarker for lymphoma in horses. Serum samples were collected from clinically normal horses (nâ=â37), horses with lymphoma (nâ=â23), horses with non-haematopoietic neoplasia (nâ=â9) and horses with inflammatory disease (nâ=â14). sTK was measured using a radioenzyme assay. A reference cut-off value ofâ<2.7âU/L (meanâ+â2 standard deviations, SDs) was established using data from clinically normal horses. sTK activity (meanâ±âSD) was 26.3â±â91.5âU/L (range 0.8-443âU/L) for horses with lymphoma, 2.3â±â1.4âU/L (range 0.6-5.7âU/L) for horses with non-haematopoietic neoplasia and 1.5â±â0.6âU/L (range 0.6-2.8âU/L) for horses with inflammatory disease. Horses with lymphoma had significantly higher sTK activity than horses without clinical signs of disease (Pâ<0.01), horses with inflammatory disease (Pâ<0.01) and horses with non-haematopoietic neoplasia (Pâ<0.05). sTK activity is a potentially useful biomarker for equine lymphoma.